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Abstract: We report the evaluation of cytotoxicity of a new type of engineered nanomaterials, FePt@CoS2
yolk-shell nanocrystals, synthesized by the mechanism of the Kirkendall effect when FePt nanoparticles
serve as the seeds. The cytotoxicity of FePt@CoS2 yolk-shell nanocrystals, evaluated by MTT assay,
shows a much lower IC50 (35.5 ( 4.7 ng of Pt/mL for HeLa cell) than that of cisplatin (230 ng of Pt/mL). In
the control experiment, cysteine-modified FePt nanoparticles exhibit IC50 at 12.0 ( 0.9 µg of Pt/mL.
Transmission electron microscopy confirms the cellular uptake of FePt@CoS2 nanocrystals, and the
magnetic properties analysis (SQUID) proves the release of FePt nanoparticles from the yolk-shell
nanostructures after cellular uptake. These results are significant because almost none of the platinum-
based complexes produced for clinical trials in the past 3 decades have shown higher activity than that of
the parent drug, cisplatin. The exceptionally high toxicity of FePt@CoS2 yolk-shell nanocrystals (about 7
times higher than that of cisplatin in terms of Pt) may lead to a new design of an anticancer nanomedicine.
Introduction
This paper reports the potent cytotoxicity of FePt@CoS2
yolk-shell nanocrystals toward cancer cells (e.g., HeLa cells)
and bacteria (e.g.,Bacillus spp.). Recently, the rapid develop-
ment of nanoscale science and technology1 has led to increased
research efforts into the applications of nanomaterials in biology
and medicine.2 Cobalt chalcogenide hollow nanocrystals, first
reported by Yin and co-workers,3 represent a novel class of
engineered nanomaterials that may find broad applications in
nano-optics system, catalysis, and drug delivery. Cobalt chal-
cogenide hollow nanocrystals form easily by the mechanism
of the Kirkendall effect.3,4 During the formation of the hollow
structure, cobalt atoms diffuse toward the outer layer to generate
the void. In this process, many pores also form in the cobalt
chalcogenide shell. As demonstrated by Yin et al., small
molecules such as hydrogen, ethylene, and ethane are able to
enter into the interior of the shell or diffuse out of the shell
freely through the pores.3 This result implies that water
molecules should cross the porous shell because of the polar
surface of CoxSy, which would further allow ions to pass through
the shell. Therefore, the yolk or the core inside the shell can
interact with biological systems via the mediation of water. The
successful synthesis of Pt@CoO yolk-shell nanostructures3 and
the well-known anticancer drug based on the binding of platinum
ions to DNA5 (e.g., cisplatin) encouraged us to evaluate the
cytotoxicity of yolk-shell nanostructures containing platinum
as a potential candidate for the development of an anticancer
nanomedicine. To monitor the dissolution of the yolk, we chose
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FePt nanoparticles as the seeds to produce FePt@CoS2 yolk-
shell nanocrystals because the superparamagnetism of FePt
nanoparticles6 should allow one to monitor the dissolution of
the yolk using a sensitive instrument such as a superconducting
quantum interference device (SQUID).
After making the FePt@CoS2 yolk-shell nanocrystals, we
used an MTT assay of HeLa cells to evaluate the cytotoxicity
of the FePt@CoS2 nanocrystals. The MTT analysis indicated
that the IC50 (the concentration of drug required to inhibit cell
growth by 50% compared to the control) of the FePt@CoS2
nanocrystals is about 35.5( 4.7 ng of Pt/mL, which is much
lower than that of cisplatin (230 ng of Pt/mL).7 These results
are significant because almost none of the platinum-based
complexes produced for clinical trials in the past 3 decades has
shown higher activity than that of the parent drug, cisplatin.7
On the other hand, few nanomaterials have been studied for
anticancer therapy. The exceptionally high anticancer activity
of FePt@CoS2 yolk-shell nanocrystals (about 7 times higher
than that of cisplatin in terms of Pt) may lead to a new class of
candidates for use as anticancer drugs.
Results and Discussion
After obtaining FePt nanoparticles by the thermal decomposi-
tion of Pt(acac)2 and Fe(CO)5 according to the procedure
reported by Sun and co-workers,6 without any separation and
purification, we directly injected the 1,2-dichlorobenzene solu-
tion of Co2(CO)8 into the refluxing solution containing oleic
acid, FePt nanoparticles, and trioctylphosphine oxide (TOPO)
surfactant to give the FePt@Co core-shell intermediates
(Supporting Information, Figure S1). After another 30 min,
injection of a solution of sulfur in 1,2-dichlorobenzene into the
hot mixture resulted in a black dispersion of FePt@CoS2 yolk-
shell nanocrystals within a few seconds. As shown in the
transmission electron microscopy (TEM) image (Figure 1a), the
FePt@CoS2 yolk-shell nanocrystals are similar to Pt@CoO
yolk-shell nanocrystals,3 indicating that the same Kirkendall
effect process on cobalt layers affords the FePt@CoS2 y lk-
shell nanocrystals. The high-resolution TEM (HRTEM) image
(Figure 1b) suggests that both the FePt parts and the CoS2 parts
are crystalline. Energy-dispersive X-ray spectrometric (EDX)
analysis (Figure 1c,d) further confirms that the core mainly
consists of Fe and Pt and the shell mainly consists of Co and
S. Moreover, X-ray photoelectron spectroscopic (XPS) measure-
ment of FePt@CoS2 yolk-shell nanocrystals (Figure S2),
performed immediately after the growth of the CoS2 shell, gives
dominant signals of Co and S in the spectrum, with very weak
peaks of Fe and Pt or even the absence of them. The XPS
measurement on the surface of the yolk-shell nanocrystals thus
supports the mechanism of the growth of the shell because the
XPS signal strongly depends upon the distance of the constituent
atoms from the surface of the nanocrystals. X-ray fluorescence
(6) Sun, S. H.; Murray, C. B.; Weller, D.; Folks, L.; Moser, A.Science2000,
287, 1989.
(7) Giovagnini, L.; Ronconi, L.; Aldinucci, D.; Lorenzon, D.; Sitran, S.;
Fregona, D.J. Med. Chem.2005, 48, 1588.
Figure 1. Characterization of FePt@CoS2 yolk-shell nanocrystals. (a) TEM and (b) HRTEM images of FePt@CoS2 y lk-shell nanocrystals. EDX analysis
of the core part (c) and the shell part (d), corresponding to regions 1 and 2 in panel b, respectively.
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spectroscopic (XRF) analysis indicates that the ratio of Co and
S is 1:2, and it also shows that the ratio of FePt and CoS2 is
about 1:65 (Figure S3). Magnetization measurement also
confirms the superparamagnetic character of the FePt@CoS2
yolk-shell nanocrystals: standard zero-field cooling (ZFC) and
field cooling (FC) measurements (Figure S3) give an estimated
blocking temperature of∼14 K for the FePt@CoS2 yolk-shell
nanocrystals, which have a coercivity (Hc) of ∼350 Oe with a
little hysteretic behavior at 5 K according to the field-dependent
magnetization measurement. The well-defined block temperature
excludes dipolar interactions between FePt magnetic nanopar-
ticles, which agrees with the yolk-shell nanostructures (i.e.,
the CoS2 shells minimize the interactions of the FePt yolks).
After complete removal of their surfactant layers according
to the reported procedure,3 the FePt@CoS2 yolk-shell nano
crystals were no longer able to disperse in hexane but were
dispersed very well in water by a brief ultrasonic treatment
without any surface modification. This exceptionally good
dispersion of FePt@CoS2 nanocrystals in water proves the
hydrophilicity of the CoS2 surface and facilitates the evaluation
of their cytotoxicity. Zeta potential analysis of the nanoparticles
proves a negatively charged surface of FePt@CoS2 nanocrystals,
indicating that the surface is sulfide-rich. After being incubated
with FePt@CoS2 nanocrystals (5µg/mL) for in vitro experi-
ments, the number of dead HeLa cells increased dramatically
with the time of incubation (Figure 2a-c), compared to the
control experiment (Figure 2d). After 72 h of incubation, almost
all of the HeLa cells were dead (Figure 2c), indicating the high
Figure 2. Cytotoxicity analyses of FePt@CoS2 yolk-shell nanocrystals
on HeLa cells. Optical microscopy images of HeLa cells incubated for (a)
24, (b) 48, and (c) 72 h with 5µg/mL of FePt@CoS2 nanocrystals and (d)
for 48 h with only the growth medium as the negative control (the scale
bars presented in panel d is the same for panels a-c). (e) Results of MTT
assay of FePt@CoS2 yolk-shell nanocrystals on HeLa cells at 1.0, 2.0,
and 4.0µg/mL, respectively.
Figure 3. Transformation of FePt@CoS2 yolk-shell nanocrystals before
and after incubation with HeLa cells. (a) TEM and (b) HRTEM images of
FePt@CoS2 yolk-shell nanocrystals dispersed in deionized water for more
than 3 days but not incubated with HeLa cells. (c) Representative TEM
image of mitochondria from HeLa cells incubated with 4.0µg/mL of
FePt@CoS2 yolk-shell nanocrystals for 3 days. (d) Magnification of the
TEM image in panel c. (e) HRTEM image of FePt@CoS2 yolk-shell
nanocrystals in mitochondria of HeLa cells: a few hollow CoS2 nanocrystals
without FePt cores are randomly dispersed in the organelles (mitochondria).
Figure 4. Illustration of a possible mechanism accounting for FePt@CoS2
yolk-shell nanocrystals killing HeLa cells. After cellular uptake, FePt
nanoparticles were oxidized to give Fe3+ (omitted for clarity) and Pt2+ ions
(yellow). The Pt2+ ions enter into the nucleus (and mitochondria), bind to
DNA, and lead to apoptosis of the HeLa cell.
A R T I C L E S Gao et al.
1430 J. AM. CHEM. SOC. 9 VOL. 129, NO. 5, 2007
cytotoxicity of FePt@CoS2. Upon death, HeLa cells detached
from the surface and sprouted multiple small, white buds around
the surface of the cells (Figure S4), suggesting the apoptosis of
the HeLa cells.8 Evaluation by MTT assay over a range of doses
of FePt@CoS2 nanocrystals (Figure 2e) indicates their IC50 at
about 1.5( 0.2 µg/mL, which corresponds to about 35.5(
4.7 ng of Pt/mL according to the composition of FePt@CoS2
nanocrystals. This value is much lower than the recorded IC50
for cisplatin (230 ng of Pt/mL) in terms of the amount of
platinum.7 The slow dissolution of FePt cores likely increases
the cytotoxicity of the york-shell nanoparticles, which agrees
with the continuing cell death over time (Figure 2e). Because
few anticancer drugs have shown IC50 values lower than that
of cisplatin in terms of the amount of platinum, this result
suggests that FePt@CoS2 may serve as a useful lead for
developing anticancer nanomedicine. Moreover, the minimum
inhibitory concentration (MIC) value of FePt@CoS2 nanocrys-
tals againstBacillus subtilis(ATCC 11774) is about 10µg/
mL, suggesting that FePt@CoS2 nanocrystals also have anti-
bacterial ability (Figure S5).
We used TEM to examine the transformation of the
FePt@CoS2 nanocrystals after they were incubated with HeLa
cells. As shown in Figure 3, the FePt@CoS2 yolk-shell
nanocrystals dispersed well in deionized water and showed no
structure evolution after more than 3 days (Figure 3a,b). After
being incubated with HeLa cells for 3 days at 37°C and 5%
CO2, many nanocrystals were observed by TEM in organelles
such as mitochondria from the HeLa cells (Figure 3c,d),
indicating the cellular uptake of FePt@CoS2 yolk-shell nano
crystals. One interesting observation from the TEM image is
that there are no more FePt@CoS2 yolk-shell nanocrystals
(Figure 3d) except for some hollow nanospheres (or destroyed
hollow nanostructures) in mitochondria bodies, suggesting that
the FePt@CoS2 yolk-shell nanocrystals lose the FePt yolks and
can enter into organelles after cellular uptake. The HRTEM
image further confirms that the size of hollow nanospheres
(Figure 3e) in the cells is similar to the size of CoS2 shell of
the FePt@CoS2 yolk-shell nanocrystals (Figure 3b). The CoS2
hollow nanospheres still remain crystalline after cellular uptake.
On the basis of the TEM results and the endocytosis-like
pathways,9 we suggest the following plausible process of
transformation of FePt@CoS2 nanocrystals when they incubated
with HeLa cells: Being surrounded by cytoplasmic extensions,
the FePt@CoS2 nanocrystals are easily engulfed in the cell to
form a vesicle, known as a phagosome. The phagosome could
be recognized by one or more primary lysosomes which fuse
with the phagosome to form a secondary lysosome. In the
secondary lysosome, with a low-pH (pH< 5.5) environment,10
FePt cores are easily oxidized and destroyed because of the
reactivity of uncoated FePt nanoparticles. When digestion is
complete, the lysosomal membrane may rupture and discharge
its contents (including hollow CoS2 nanospheres and platinum
and iron ions) into the cytoplasm. The hollow CoS2 nanospheres
may then attach onto or enter into organelles, and Pt2+ ions
also can easily enter into organelles such as nucleus and
mitochondria. In order to simulate the process of digestion of
FePt@CoS2 nanocrystals in HeLa cells, we incubated FePt@CoS2
nanocrystals with phosphate-buffered saline (pH) 4.98) under
the same conditions (i.e., 37°C and 5% CO2). The FePt core
parts were easily destroyed under these simulation conditions
and dissolved over time. After 3 days, although a few CoS2
shells are partially destroyed because of the acidic environment,
the FePt parts have almost completely disappeared according
the TEM images and EDX analysis (Figure S6). The simulation
experiments support the endocytosis and digestion process of
(8) Zhang, W. H.; Tsan, R.; Schroit, A. J.; Fidler, I. J.Cancer Res.2005, 65,
11529.
(9) Mellman, I.Annu. ReV. Cell DeV. Biol. 1996, 12, 575.
(10) Demaurex, N.News Physiol. Sci.2002, 17, 1.
Figure 5. Temperature-dependent magnetization (ZFC/FC) measured with
a magnetic field of 200 Oe. Cells suspension before (a) and after (b)
incubation with FePt@CoS2 nanocrystals for 3 days. (c) Difference between
the curves shown in panels a and b after two magnetization measurements
(extracted by subtracting the signal of control cells from that of FePt@CoS2
treated cells. The endogenous magnetic species inside the cells may
contribute to the systematic difference between FC and ZFC curves.
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FePt@CoS2 yolk-shell nanocrystals in HeLa cells. Moreover,
the slow dissolution of the FePt parts clearly correlates with
the increased toxicity with increasing time of incubation,
indicated by the MTT assay (Figure 2e).
Therefore, we propose the mechanism of cytotoxicity of
FePt@CoS2 yolk-shell nanocrystals against the HeLa cells as
shown in Figure 4: The nanosized FePt particles (∼2 nm in
diameter) have no surface protection group after the formation
of CoS2 shells via the Kirkendall effect, and thus they are highly
reactive. After cellular uptake, under the acidic environment
inside the secondary lysosomes, FePt cores are oxidized and
destroyed to become metal ions because the reactivity of
unprotected iron promotes the disintegration of FePt to release
platinum ions (Pt2+). The permeability (or the rupture) of CoS2
shells allows these Pt2+ ions to diffuse out of the shells easily
and enter into the nucleus and mitochondria, damage the DNA
double-helix chains by coordinating with 5′-GG-3′ bases of
DNA,11 and lead to the apoptosis of the HeLa cells.
To further verify the mechanism proposed in Figure 4, we
measured temperature-dependent magnetization (ZFC/FC) of
cells before and after they were incubated (3 days at 37°C and
5% CO2) with FePt@CoS2 yolk-shell nanocrystals. The
magnetization curves in Figure 5a indicate that the cells, before
being incubated with FePt@CoS2 nanocrystals, are mainly
diamagnetic, as we expected for the organic compounds and
the cells. The strong increase in magnetization in the low-
temperature region should be due to the paramagnetic species
in cells (e.g., metal centers of metalloenzymes). After the cells
were incubated with FePt@CoS2 nanocrystals for 3 days, the
magnetization curves for the cells (Figure 5b) were certainly
different from those of the control sample (Figure 5a) and those
of the FePt@CoS2 nanocrystals (Figure S3). In addition to the
contribution of the paramagnetic ions that inherently associate
with the cells, there is another positive signal in the temperature
range 6-250 K (Figure 5c, extracted by subtracting the signal
of the control cells from that of FePt@CoS2-treated cells). The
broad peak between 6 and 250 K likely arises from magnetic
clusters of iron oxides or iron hydroxides with a broad size
distribution because of the reaction of iron ions with water after
the degradation of the FePt core. Together with the TEM results,
these magnetic data also indirectly support the mechanism
illustrated in Figure 4.
To prove that the observed ultrahigh cytotoxicity of the
FePt@CoS2 yolk-shell nanocrystals mainly arises from the
uncoated FePt core, we performed a series of control experi-
(11) Yang, D.; van Boom, S. S.; Reedijk, J.; van Boom, J. H.; Wang, A. H.
Biochemistry1995, 34, 12912. Takahara, P. M.; Rosenzweig, A. C.;
Frederick, C. A.; Lippard, S. J.Nature1995, 377, 649. Takahara, P. M.;
Frederick, C. A.; Lippard, S. J.J. Am. Chem. Soc.1996, 118, 12309.
Figure 6. TEM images and cytotoxicity analyses of three control samples. TEM images of (a) CoS2 hollow nanospheres, (b) FePt@Fe3O4 core-shell
nanoparticles, and (c) cysteine-coated FePt nanoparticles (inset: HRTEM images). (d) Results of MTT assay for 24 h of CoS2 ollow nanospheres, FePt@Fe3O4
core-shell nanoparticles, and cysteine-coated FePt nanoparticles on HeLa cells at 5.0, 10.0, and 20.0µg/mL, respectively. (e) Results of MTT assay for 24
h of FePt@CoS2 yolk-shell nanocrystals, CoS2 hollow nanospheres, FePt@Fe3O4 core-shell nanoparticles, and FePt-Cys nanoparticles on HeLa cells at
1.0, 2.0, and 4.0µg/mL, respectively, indicating that CoS2 hollow nanospheres, FePt@Fe3O4 core-shell nanoparticles, and FePt-Cys nanoparticles have
much lower cytotoxicity than FePt@CoS2 yolk-shell nanocrystals.
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ments by incubating HeLa cells with CoS2 hollow nanospheres
(Figure 6a), FePt@Fe3O4 core-shell nanoparticles (Figure 6b),
and cysteine-coated FePt nanoparticles (Figure 6c). CoS2 h llow
nanospheres were synthesized as in the previous procedure3 but
without FePt nanoparticles. FePt@Fe3O4 core-shell nanopar-
ticles were synthesized as described in a previous publication.12
According to the cytotoxicity assay shown in Figure 6, CoS2
hollow nanocrystals have a low cytotoxicity and exhibit an IC50
of 13.8 ( 1.8 µg/mL (Figure 6d). FePt@Fe3O4 core-shell
nanoparticles show very little cytotoxicity (Figure 6d), suggest-
ing that FePt nanoparticles inside the Fe3O4 shells are very stable
and resistant to oxidization because of the biocompatible,
compact Fe3O4 shells. Because the organic protection layer
retards the oxidation of FePt nanoparticles, cysteine-coated FePt
nanoparticles also show very low cytotoxicity and exhibit an
IC50 of 15.5 ( 1.2 µg/mL (Figure 6d), corresponding to 12.0
( 0.9 µg of Pt/mL. Compared with FePt@CoS2 yolk-shell
nanocrystals, the three control samples, CoS2 hollow nano-
spheres, FePt@Fe3O4 core-shell nanoparticles, and FePt-Cys
nanoparticles, have lower cytotoxicity (Figure 6e), which
supports the mechanism illustrated in Figure 4. The results of
MTT assays using CoS2 hollow nanospheres and FePt-Cys
nanoparticles for 3 days showed that the cells recover dramati-
cally after day two (Figure S7), indicating that these two
compounds only possess acute toxicity.
Conclusion
In summary, we have synthesized a new yolk-shell nano-
structure, FePt@CoS2 yolk-shell nanocrystals, and evaluated
its cytotoxicity. Although the ultrahigh cytotoxicity originating
in the uncoated FePt yolk in the FePt@CoS2 nanocrystals would
also be associated with side effects (similar to cisplatin), this
type of yolk-shell or core-shell nanostructures may lead to
novel nanomedicines for treating cancers, resulting from
decorating the surface of the FePt@CoS2 nanocrystals with
cancer-targeting antibodies.
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